Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy

Watanabe, Dai; Suzuma, Kiyoshi; Suzuma, Izumi; Ohashi, Hirokazu; Ojima, T.; Kurimoto, Masafumi; Murakami, Tomoaki; Kimura, Tomio; Takagi, Hitoshi

doi:10.1016/j.ajo.2004.10.004

Cited by 188 publications

(140 citation statements)

References 22 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Erythropoietin appears to act independently of VEGF 208 , whereas angiopoietin-2 appears to act synergistically with VEGF 209 . Reduced somatostatin expression may also be an early event in DR 211 .…”

Section: Angiogenesis and Production Of Vascular Endothelial Growth Fmentioning

confidence: 99%

Adherence to diabetic eye examination guidelines in Australia: the National Eye Health Survey

Foreman

Keel

Xie

et al. 2017

Medical Journal of Australia

View full text Add to dashboard Cite

Section: Angiogenesis and Production Of Vascular Endothelial Growth Fmentioning

confidence: 99%

Adherence to diabetic eye examination guidelines in Australia: the National Eye Health Survey

Foreman

Keel

Xie

et al. 2017

Medical Journal of Australia

View full text Add to dashboard Cite

“…In PDR, the growth of new vessels from the retina or optic nerve, is thought to occur as a result of vascular endothelial grow factor (VEGF) release into the vitreous cavity as a response to ischaemia. [2][3][4] Because VEGF has been shown to play a major role in retinal neovascularization (RN), 2,3 although other factors may be involved as well, 5,6 anti-VEGF treatments have been hypothesized as an alternative adjunctive treatment for RN. 7,8 Bevacizumab (Avastin TM Genentech Inc., San Francisco, CA, USA) is a complete full-length humanized antibody that binds to all subtypes of VEGF and is successfully used in tumour therapy as a systemic drug.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up

Arévalo¹,

Sánchez³

et al. 2007

Eye

117

101

View full text Add to dashboard Cite

Aims To study the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR). Methods Retrospective study of patients with RN due to PDR who were treated with at least one intravitreal injection of 1.25 or 2.5 mg of bevacizumab. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits.Results Forty-four eyes of 33 patients with PDR and a mean age of 57.2-years (range: 23-82 years) participated in the study. Thirty-three eyes (75%) had previous panretinal photocoagulation (PRP). Twenty-seven eyes (61.4%) showed total regression of RN on fundus examination with absence of fluorescein leakage, 15 eyes (34.1%) demonstrated partial regression of RN on fundus examination and FA. Follow-up had a mean of 28.4 weeks (range from 24 to 40 weeks). BCVA and OCT demonstrated improvement (Po0.0001). Three eyes without previous PRP ('naive' eyes) and with vitreous haemorrhage have avoided vitreo-retinal surgery. One eye (2.2%) had PDR progression to tractional retinal detachment requiring vitrectomy, and one eye (2.2%) had vitreous haemorrhage with increased intraocular pressure (ghost cell glaucoma). No systemic adverse events were observed. Conclusions Intravitreal bevacizumab resulted in marked regression of RN in patients with PDR and previous PRP, and rapid resolution of vitreous haemorrhage in three naive eyes. Six-months results of intravitreal bevacizumab at doses of 1.25 or 2.5 mg in patients with PDR do not reveal any safety concerns.

show abstract

“…72 An increase in Ang-2/Ang-1 ratio was found to be associated with angiogenic activity in patients with diabetic retinopathy. 73 Whether this system is altered in the brain microvasculature in diabetes needs to be established.…”

Section: Diabetes and Neovascularizationmentioning

confidence: 99%

Cerebral Neovascularization in Diabetes: Implications for Stroke Recovery and beyond

Ergul

Abdelsaid

Fouda

et al. 2014

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

Neovascularization is an innate physiologic response by which tissues respond to various stimuli through collateral remodeling (arteriogenesis) and new vessel formation from existing vessels (angiogenesis) or from endothelial progenitor cells (vasculogenesis). Diabetes has a major impact on the neovascularization process but the response varies between different organ systems. While excessive angiogenesis complicates diabetic retinopathy, impaired neovascularization contributes to coronary and peripheral complications of diabetes. How diabetes influences cerebral neovascularization remained unresolved until recently. Diabetes is also a major risk factor for stroke and poor recovery after stroke. In this review, we discuss the impact of diabetes, stroke, and diabetic stroke on cerebral neovascularization, explore potential mechanisms involved in diabetes-mediated neovascularization as well as the effects of the diabetic milieu on poststroke neovascularization and recovery, and finally discuss the clinical implications of these effects.

show abstract

Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy

Cited by 188 publications

References 22 publications

Adherence to diabetic eye examination guidelines in Australia: the National Eye Health Survey

Adherence to diabetic eye examination guidelines in Australia: the National Eye Health Survey

Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up

Cerebral Neovascularization in Diabetes: Implications for Stroke Recovery and beyond

Contact Info

Product

Resources

About